Ondine Biomedical's Steriwave Adopted by Canada's Largest Cardiac Centre
Why we think this is good
The RNS announces that the Ottawa Heart Institute, a leading cardiac care centre in Canada, has adopted Ondine Biomedical's Steriwave nasal photodisinfection technology as a standard of care for cardiac surgeries. This is a positive development for the company, as it demonstrates the growing adoption of its innovative infection prevention solution by a prestigious healthcare institution. The news suggests Ondine is making progress in expanding the commercial reach of its products, which is a good sign for the company's future prospects.
Key Points
- Ottawa Heart Institute, Canada's largest cardiac centre, has adopted Ondine's Steriwave nasal photodisinfection as standard of care for cardiac surgeries
- Steriwave is a light-activated, non-antibiotic antimicrobial therapy that rapidly eradicates nasal pathogens associated with surgical site infections
- OHI is a leading cardiac care institution recognized internationally for its expertise and commitment to patient safety and innovation
- Adoption of Steriwave by OHI further validates the product's effectiveness and Ondine's progress in commercializing its technologies
Summary
Ondine Biomedical Inc. (OBI) has announced that the University of Ottawa Heart Institute (OHI), one of Canada's leading cardiac care centres, has adopted Steriwave® nasal photodisinfection as a standard of care for all cardiac surgeries. This decision reinforces OHI's commitment to patient safety and innovation in infection prevention. OHI is Canada's largest and foremost cardiovascular health centre, recognized internationally for its expertise in cardiac care, research, and education. The adoption of Steriwave by OHI further validates the product as an effective solution for infection control and demonstrates Ondine's progress in expanding the commercial reach of its innovative technologies.